title: Sustained benefit of a community and professional intervention to increase acute stroke therapy.
abstract: BACKGROUND
  The ultimate test of an educational intervention is the sustainability of the effect after the intervention ceases.
  
  
  METHODS
  The TLL Temple Foundation Stroke Project was a quasi-experimental study aimed at increasing Food and Drug Administration-approved acute stroke therapy in a nonurban community in east Texas. During the intensive community and professional intervention (phase 2), significantly more patients with acute stroke received intravenous tissue plasminogen activator (tPA) compared with the preintervention period (phase 1). In the comparison community, no change was noted. We present the results of tPA treatment in the 6 months after the intervention ended (phase 3).
  
  
  RESULTS
  Two hundred thirty-eight patients had a validated stroke during phase 3. Among patients who experienced an ischemic stroke, 11.2% in the intervention group received intravenous tPA compared with 2.2% in phase 1 (P =.007). In the comparison group, 1.4% received intravenous tPA in phase 3 compared with 0.7% in phase 1 (P>.99). Among eligible candidates for treatment, 69.2% were treated in phase 3 in the intervention community compared with 13.6% in phase 1 (P =.002). In the comparison group, 20.0% were treated in phase 3 compared with 6.7% in phase 1 (P =.45). There was 1 protocol violation among the 9 patients treated in the intervention community in phase 3.
  
  
  CONCLUSIONS
  There was a sustained benefit of the intervention in increasing tPA treatments in the intervention community even after cessation of the educational effort. Treatments in the control community remained few through all 3 phases of the study. A carefully planned multilevel intervention can improve community stroke treatments even in a nonurban community.
authors.affiliation: Stroke Program, Department of Neurology, The University of Texas Medical School at Houston, USA. lmorgens@umich.edu
authors.forename: Lewis B
authors.initials: LB
authors.lastname: Morgenstern
authors.forename: L Kay
authors.initials: LK
authors.lastname: Bartholomew
authors.forename: James C
authors.initials: JC
authors.lastname: Grotta
authors.forename: Lara
authors.initials: L
authors.lastname: Staub
authors.forename: Mary
authors.initials: M
authors.lastname: King
authors.forename: Wenyaw
authors.initials: W
authors.lastname: Chan
mesh_terms: D004363:Drug Utilization; D004502:Education, Medical, Continuing; D004636:Emergency Service, Hospital; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006266:Health Education; D006801:Humans; D007262:Infusions, Intravenous; D010043:Outcome and Process Assessment, Health Care; D010348:Patient Care Team; D010865:Pilot Projects; D010818:Practice Patterns, Physicians'; D011785:Quality Assurance, Health Care / Q000458:organization & administration*; D020521:Stroke / Q000188:drug therapy*; D000071939:Stroke Rehabilitation; D013781:Texas; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator